Diurnal Group announces commercial launch of Efmody in the UK
LONDON, UK: Diurnal Group announced the commercial launch of Efmody (hydrocortisone modified-release hard capsules) in the United Kingdom as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). The launch of…